Dark Forest Capital Management LP Sells 19,683 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Dark Forest Capital Management LP cut its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 39.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 29,693 shares of the biotechnology company’s stock after selling 19,683 shares during the period. Dark Forest Capital Management LP’s holdings in BioCryst Pharmaceuticals were worth $223,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BCRX. SkyView Investment Advisors LLC grew its stake in BioCryst Pharmaceuticals by 30.0% in the third quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after acquiring an additional 3,000 shares during the period. Franklin Resources Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 177.8% in the 3rd quarter. Franklin Resources Inc. now owns 263,748 shares of the biotechnology company’s stock worth $1,968,000 after purchasing an additional 168,790 shares in the last quarter. Exome Asset Management LLC acquired a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at $1,493,000. Principal Financial Group Inc. increased its stake in BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after purchasing an additional 375,890 shares in the last quarter. Finally, KBC Group NV raised its holdings in BioCryst Pharmaceuticals by 80.1% during the fourth quarter. KBC Group NV now owns 10,198 shares of the biotechnology company’s stock worth $77,000 after buying an additional 4,537 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

Shares of BCRX stock opened at $8.44 on Wednesday. The firm has a market cap of $1.76 billion, a price-to-earnings ratio of -13.84 and a beta of 1.75. BioCryst Pharmaceuticals, Inc. has a 52 week low of $4.11 and a 52 week high of $9.50. The firm’s 50-day simple moving average is $7.68 and its two-hundred day simple moving average is $7.77.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $131.50 million during the quarter, compared to analyst estimates of $126.64 million. During the same quarter last year, the firm posted $0.28 EPS. The company’s revenue was up 40.8% compared to the same quarter last year. Analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Royal Bank of Canada reiterated an “outperform” rating and set a $11.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, April 11th. JMP Securities reissued a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. HC Wainwright restated a “buy” rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. Needham & Company LLC reiterated a “buy” rating and set a $15.00 price target on shares of BioCryst Pharmaceuticals in a report on Thursday, April 10th. Finally, Wedbush started coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price target for the company. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, BioCryst Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $16.13.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.